Solvonis Therapeutics plc
SVNS.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | – | £0 | £0 | £347 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | – | £0 | £18 | £317 |
| Gross Profit | – | £0 | -£18 | £30 |
| % Margin | – | – | – | 8.6% |
| R&D Expenses | – | £0 | £0 | £0 |
| G&A Expenses | – | £246 | £526 | £1,085 |
| SG&A Expenses | – | £246 | £544 | £1,218 |
| Sales & Mktg Exp. | – | £0 | £18 | £133 |
| Other Operating Expenses | – | £103 | -£139 | £900 |
| Operating Expenses | – | £349 | £405 | £2,118 |
| Operating Income | – | -£349 | -£405 | -£2,088 |
| % Margin | – | – | – | -601.7% |
| Other Income/Exp. Net | – | £0 | -£64 | £94 |
| Pre-Tax Income | – | -£349 | -£469 | -£1,994 |
| Tax Expense | – | £0 | £0 | £0 |
| Net Income | – | -£335 | -£626 | -£1,994 |
| % Margin | – | – | – | -574.6% |
| EPS | – | -0.003 | -0.006 | -0.019 |
| % Growth | – | 46.7% | 68.8% | – |
| EPS Diluted | – | -0.003 | -0.005 | -0.019 |
| Weighted Avg Shares Out | – | 104,057 | 104,057 | 104,022 |
| Weighted Avg Shares Out Dil | – | 124,310 | 124,310 | 104,017 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | £0 | £0 | £0 |
| Interest Expense | – | £0 | £0 | £0 |
| Depreciation & Amortization | – | £0 | £57 | £75 |
| EBITDA | – | -£349 | -£348 | -£1,919 |
| % Margin | – | – | – | -553% |